MedTrace Logo

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

NCT02976753 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 361

Last updated 2024-10-02

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A over a 24-month prospective period. Data will also be collected for a 12 month retrospective period.

Conditions

Interventions

DRUG

efmoroctocog alfa

extended half-life factor VIII product

DRUG

Factor VIII

conventional factor VIII product

Sponsors & Collaborators

  • ICON plc

    collaborator INDUSTRY

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Study Physician, MD · Sweden Orphan Biovitrum

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2021-11-03
Completion
2021-11-03

Countries

  • Austria
  • Belgium
  • Finland
  • France
  • Italy
  • Norway
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02976753 on ClinicalTrials.gov